Nieuws

6-2-2009

Innate Pharma reports operating revenue of 12.9 million euros for 2008

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), a biopharmaceutical company developing first-in-class drug candidates targeting the innate immune system, today announces an operating revenue of 12.9 million Euros for the year 2008. Turnover for the year amounted to 7.5 million Euros, including 1.6 million Euros in the fourth quarter ended December 31, 2008.

The following table breaks down the operating revenue and compares 2008 to 2007:

Fiscal year ended December 31,

The following table shows the breakdown of the turnover for the fourth quarters of 2007 and 2008:

Fourth quarter ended December 31, 

In 2007 and 2008, the revenue from collaboration and licensing agreements mostly consisted in revenue from the collaboration and licensing agreement with Novo Nordisk A/S.

Cash, cash equivalents and current financial instruments

As of December 31, 2008, cash, cash equivalents and current financial instruments of the Company amounted to 33,830 thousand Euros.

The research tax credit balance receivable from the French State amounted to 10,395 thousand Euros as of December 31, 2008. In accordance with the French revised finance law for 2009, enacted in early 2009, the Company is requesting the immediate refund of this balance receivable.

As of December 31, 2008, the Company had 3,486 thousand Euros in borrowings related to Oseo repayable loans and other bank loans.

The renovation of the premises (headquarters and main laboratories in Marseilles) acquired in June 2008 was completed in late 2008. The total lease financing obtained for this transaction amounts to 5,049 thousand Euros as of December 31, 2008.
 

PDF-file [33kb]

Engelse versie - Franse versie